Skip to main content
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.


Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Table of Contents

Last Updated: October 19, 2021

Below is an overview of the sections found in the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.

What’s New in the Guidelines

Updated COVID-19 Treatment Guidelines Panel’s Statement on the Prioritization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment or Prevention of SARS-CoV-2 Infection When There Are Logistical or Supply Constraints



  • Overview of COVID-19
  • Testing for SARS-CoV-2 Infection
  • Prevention of SARS-CoV-2 Infection
  • Clinical Spectrum of SARS-CoV-2 Infection

Clinical Management

  • Clinical Management Summary
  • General Management of Nonhospitalized Patients With COVID-19
  • Therapeutic Management of Nonhospitalized Adults With COVID-19
  • Therapeutic Management of Hospitalized Adults With COVID-19

Critical Care

  • Care of Critically Ill Adult Patients With COVID-19 (Summary Recommendations)
  • General Considerations
  • Infection Control
  • Hemodynamics
  • Oxygenation and Ventilation
  • Acute Kidney Injury and Renal Replacement Therapy
  • Pharmacologic Interventions
  • Extracorporeal Membrane Oxygenation

Antiviral Therapy

  • Antiviral Drugs That Are Approved or Under Evaluation for the Treatment of COVID-19 (Summary Recommendations)
  • Remdesivir
    • Table 2a. Remdesivir: Selected Clinical Data
  • Chloroquine or Hydroxychloroquine and/or Azithromycin
    • Table 2b. Chloroquine or Hydroxychloroquine and/or Azithromycin: Selected Clinical Data
  • Ivermectin
    • Table 2c. Ivermectin: Selected Clinical Data
  • Lopinavir/Ritonavir and Other HIV Protease Inhibitors
  • Nitazoxanide
    • Table 2d. Nitazoxanide: Selected Clinical Data
  • Table 2e. Characteristics of Antiviral Agents That Are Approved or Under Evaluation for the Treatment of COVID-19

Anti-SARS-CoV-2 Antibody Products

  • Anti-SARS-CoV-2 Antibody Products (Summary Recommendations)
  • Anti-SARS-CoV-2 Monoclonal Antibodies
    • Table 3a. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data
  • Convalescent Plasma
    • Table 3b. COVID-19 Convalescent Plasma: Selected Clinical Data
  • Immunoglobulins: SARS-CoV-2 Specific
  • Table 3c. Characteristics of SARS-CoV-2 Antibody-Based Products Under Evaluation for the Treatment or Prevention of COVID-19

Cell-Based Therapy Under Evaluation for the Treatment of COVID-19


  • Immunomodulators Under Evaluation for the Treatment of COVID-19 (Summary Recommendations)
  • Colchicine
  • Corticosteroids
    • Table 4a. Systemic Corticosteroids: Selected Clinical Data
    • Table 4b. Inhaled Corticosteroids: Selected Clinical Data
  • Fluvoxamine
  • Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors
    • Table 4c. Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors: Selected Clinical Data
  • Immunoglobulins: Non-SARS-CoV-2 Specific
  • Interferons (Alfa, Beta)
  • Interleukin-1 Inhibitors
  • Interleukin-6 Inhibitors
    • Table 4d. Interleukin-6 Inhibitors: Selected Clinical Data
  • Kinase Inhibitors: Janus Kinase Inhibitors and Bruton’s Tyrosine Kinase Inhibitors
  • Table 4e. Characteristics of Immunomodulators Under Evaluation for the Treatment of COVID-19

Antithrombotic Therapy in Patients With COVID-19


  • Supplements (Summary Recommendations)
  • Vitamin C
  • Vitamin D
  • Zinc

Considerations for Certain Concomitant Medications in Patients With COVID-19

Special Populations

  • Special Considerations in Pregnancy
  • Special Considerations in Children
  • Special Considerations in Adults and Children With Cancer
  • Special Considerations in Solid Organ Transplant, Hematopoietic Stem Cell Transplant, and Cellular Therapy Candidates, Donors, and Recipients
  • Special Considerations in People With HIV
  • Influenza and COVID-19

Appendix A, Table 1. COVID-19 Treatment Guidelines Panel Members

Appendix A, Table 2. COVID-19 Treatment Guidelines Panel Financial Disclosure for Companies Related to COVID-19 Treatment or Diagnostics